Search Orphan Drug Designations and Approvals
-
Generic Name: | 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4H-imidazo[4,5,1-ij] quinoline hydrochloride |
---|---|
Date Designated: | 03/26/2020 |
Orphan Designation: | Treatment of acute myeloid leukemia |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Ryvu Therapeutics S.A. Bobrzynskiego 14 Krakow Poland The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-